Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Shares Bought by IFP Advisors Inc

IFP Advisors Inc raised its position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) TSE: AUP by 31.0% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 271,132 shares of the biotechnology company's stock after buying an additional 64,107 shares during the period. IFP Advisors Inc owned about 0.19% of Aurinia Pharmaceuticals worth $2,435,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Blue Trust Inc. increased its stake in shares of Aurinia Pharmaceuticals by 3,041.4% during the fourth quarter. Blue Trust Inc. now owns 6,377 shares of the biotechnology company's stock worth $57,000 after purchasing an additional 6,174 shares in the last quarter. FMR LLC increased its stake in shares of Aurinia Pharmaceuticals by 44.8% during the third quarter. FMR LLC now owns 12,673 shares of the biotechnology company's stock worth $93,000 after purchasing an additional 3,919 shares in the last quarter. Union Bancaire Privee UBP SA purchased a new stake in shares of Aurinia Pharmaceuticals during the fourth quarter worth about $108,000. Atria Wealth Solutions Inc. purchased a new stake in shares of Aurinia Pharmaceuticals during the fourth quarter worth about $135,000. Finally, China Universal Asset Management Co. Ltd. increased its stake in shares of Aurinia Pharmaceuticals by 63.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 27,502 shares of the biotechnology company's stock worth $202,000 after purchasing an additional 10,700 shares in the last quarter. Hedge funds and other institutional investors own 36.83% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

Separately, StockNews.com lowered shares of Aurinia Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, February 19th.

Aurinia Pharmaceuticals Price Performance

AUPH traded up $0.40 on Friday, reaching $7.95. 1,849,940 shares of the company's stock were exchanged, compared to its average volume of 1,365,698. The stock has a market cap of $1.14 billion, a PE ratio of -53.00 and a beta of 1.22. Aurinia Pharmaceuticals Inc. has a twelve month low of $4.71 and a twelve month high of $10.67. The stock's fifty day moving average price is $8.17 and its 200-day moving average price is $7.79. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.60 and a quick ratio of 5.11.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.